Associated Papers
Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study.
Joris S et al.
Esmo Open, 2023
37852034 (PubMed )
Supplement: mmc2.xlsx › Blad1
Select a paper to view details